Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)

Abstract Introduction Avelumab, pembrolizumab, and enfortumab vedotin (EV) demonstrated efficacy in mUC following platinum-based chemotherapy. However, real-world data in patients with urothelial carcinoma with squamous differentiation (UCSD) are limited. The aim of this study is to assess the real-...

Descrición completa

Detalles Bibliográficos

Principais autores:	Veronica Mollica, Francesco Massari, Kazutoshi Fujita, Patrizia Giannatempo, Enrique Grande, Thomas Büttner, Maria T. Bourlon, Tarek Taha, Wataru Fukuokaya, Zin W. Myint, Renate Pichler, Kirstin Binz, Javier Molina‑Cerrillo, Jindrich Kopecky, Alfonso Gómez de Liaño, Jakub Kucharz, Ondřej Fiala, Marc R. Matrana, Ray Manneh Kopp, Mattia Alberto Di Civita, Anca Zgura, Jawaher Ansari, Randi Kihnel, Francesca De Felice, Martín Angel, Fernando Sabino M. Monteiro, Andrey Soares, Yuksel Urun, Sebastiano Buti, Daniele Santini, Matteo Santoni
Formato:	Artigo
Idioma:	Inglês
Publicado:	Springer 2026-03-01
Series:	Cancer Immunology, Immunotherapy
Assuntos:	Avelumab Enfortumab Vedotin Immunotherapy NCT05290038 Pembrolizumab Squamous differentiation
Acceso en liña:	https://doi.org/10.1007/s00262-026-04328-9
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!